Allegra and Neuroleptic malignant syndrome - a phase IV clinical study of FDA data

Summary:

Neuroleptic malignant syndrome is reported only by a few people who take Allegra.

The phase IV clinical study analyzes which people take Allegra and have Neuroleptic malignant syndrome. It is created by eHealthMe based on reports of 66,294 people who have side effects while taking Allegra from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 06, 2023

66,294 people reported to have side effects when taking Allegra.
Among them, 4 people (0.01%) have Neuroleptic malignant syndrome.

What is Allegra?

Allegra has active ingredients of fexofenadine hydrochloride. It is often used in allergies. eHealthMe is studying from 68,539 Allegra users for its effectiveness, alternative drugs and more.

What is Neuroleptic malignant syndrome?

Neuroleptic malignant syndrome (a life-threatening neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic agents) is found to be associated with 1,116 drugs and 714 conditions by eHealthMe.

Number of Allegra and Neuroleptic malignant syndrome reports submitted per year:

Could Allegra cause Neuroleptic malignant syndrome?

Gender of people who have Neuroleptic malignant syndrome when taking Allegra *:

female: 66.67 %
male: 33.33 %

Age of people who have Neuroleptic malignant syndrome when taking Allegra *:

Common drugs people take besides Allegra *:

Common side effects people have besides Neuroleptic malignant syndrome *:

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 50.00%
Weight Increased: 1 person, 25.00%
Fainting (loss of consciousness and postural tone): 1 person, 25.00%
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight): 1 person, 25.00%
Aphonia (inability to produce voice): 1 person, 25.00%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 25.00%
Balance Disorder: 1 person, 25.00%
Blood Creatinine Increased: 1 person, 25.00%
Body Height Decreased: 1 person, 25.00%
Catatonia (unresponsive to external stimuli): 1 person, 25.00%

Common conditions people have *:

Renal Failure Chronic (long lasting kidney dysfunction): 1 person, 25.00%
Psychotic Disorder: 1 person, 25.00%
Pain: 1 person, 25.00%
Osteoporosis (bones weak and more likely to break): 1 person, 25.00%
Nephrogenic Anaemia (anaemia due to kidney disease): 1 person, 25.00%
Multiple Allergies (allergy to multiple agents): 1 person, 25.00%
High Blood Cholesterol: 1 person, 25.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 25.00%
Fainting (loss of consciousness and postural tone): 1 person, 25.00%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Allegra and have Neuroleptic malignant syndrome?

Check whether Neuroleptic malignant syndrome is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .

Related studies

How severe was Neuroleptic malignant syndrome and when was it recovered:

Neuroleptic malignant syndrome in Allegra

Expand to all the drugs that have ingredients of fexofenadine hydrochloride:

Neuroleptic malignant syndrome and drugs with ingredients of fexofenadine hydrochloride

Alternative drugs to, pros and cons of Allegra:

Allegra (68,539 reports)

Common Allegra side effects:

Drug ineffective: 9,288 reports
Fatigue (feeling of tiredness): 3,823 reports
Headache (pain in head): 3,484 reports
Breathing difficulty: 3,388 reports
Dizziness: 3,082 reports
Rashes (redness): 2,992 reports
Pain: 2,960 reports

Browse all side effects of Allegra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Neuroleptic malignant syndrome treatments and more:

Neuroleptic malignant syndrome (14,359 reports)

COVID vaccines that are related to Neuroleptic malignant syndrome:

Common drugs associated with Neuroleptic malignant syndrome:

All the drugs that are associated with Neuroleptic malignant syndrome:

Neuroleptic malignant syndrome (1,116 drugs)

Common conditions associated with Neuroleptic malignant syndrome:

Schizophrenia: 2,211 reports
Depression: 1,178 reports
Bipolar disorder: 926 reports
Agitation: 642 reports
Parkinson's disease: 552 reports

All the conditions that are associated with Neuroleptic malignant syndrome:

Neuroleptic malignant syndrome (714 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fexofenadine hydrochloride (the active ingredients of Allegra) and Allegra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.